Our company has established a world leading position in the development of plant-derived cannabinoid therapeutics through its proven drug discovery and development processes, intellectual property portfolio and regulatory and manufacturing expertise.
Our lead product candidate is Epidiolex® (cannabidiol or CBD) for rare and severe childhood-onset, drug-resistant epilepsy syndromes.
We have a global pipeline of clinical stage cannabinoid candidates for both orphan and non-orphan indications with a particular focus on neurological conditions, for more information click here.
Epidiolex (CBD) is an investigational drug not approved for any indication.